Search

Start Over Keyword SARS-CoV-2

  • Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

    Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
    Authors:Rajesh M. Valanparambil, Emory UniversityJennifer Carlisle, Winship Cancer InstituteSusanne L. Linderman, Emory UniversityAkil Akthar, Emory UniversityRalph Linwood Millett, Winship Cancer InstituteLilin Lai, Emory UniversityAndres Chang, Emory UniversityAshley A. McCook-Veal, Emory UniversityJeffrey Switchenko, Emory UniversityTahseen H. Nasti, Emory UniversityManpreet Saini, Emory UniversityAndreas Wieland, Emory UniversityKelly E. Manning, Emory UniversityMadison Ellis, Emory UniversityKathryn M. Moore, Emory UniversityStephanie L. Foster, Emory UniversityKatharine Floyd, Emory UniversityMeredith E. Davis-Gardner, Emory UniversityVenkata-Viswanadh Edara, Emory UniversityMit Patel, Emory UniversityConor Steur, Emory UniversityAjay K. Nooka, Emory UniversityFelicia Green, Winship Cancer InstituteMargaret A. Johns, Winship Cancer InstituteFiona O'Brein, Winship Cancer InstituteUma Shanmugasundaram, Emory UniversityVeronika I. Zarnitsyna, Emory UniversityHasan Ahmed, Emory UniversityLindsay E. Nyhoff, Emory UniversityGrace Mantus, Emory UniversityMichael Garett, Emory UniversitySrilatha Edupuganti, Emory UniversityMadhusmita Behra, Winship Cancer InstituteRustom Antia, Emory UniversityJens Wrammert, Emory UniversityMehul S. Suthar, Emory UniversityMadhav V. Dhodapkar, Emory UniversitySuresh Ramalingam, Winship Cancer InstituterAFI aHMED, Emory University
    Date:2022
    Publisher:American Society of Clinical Oncology
    Publication Version:Final Published Version

  • Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
    Authors:Andres Chang, Emory UniversityAkil Akhtar, Emory UniversitySusanne L. Linderman, Emory UniversityLilin Lai, Emory UniversityVictor M. Orellana-Noia, Emory UniversityRajesh Valanparambil, Emory UniversityHasan Ahmed, Emory UniversityVeronika I. Zarnitsyna, Emory UniversityAshley A. McCook-Veal, Emory UniversityJeffrey M. Switchenko, Emory UniversityJean L. Koff, Emory UniversityKristie A. Blum, Emory UniversityAmy A. Ayers, Emory UniversityColin B. O'Leary, Emory UniversityMichael C. Churnetski, Emory UniversityShahana Sulaiman, Emory UniversityMelissa Kives, Emory UniversityPreston Sheng, Emory UniversityCarl W. Davis, Emory UniversityAjay K. Nooka, Emory UniversityRustom Antia, Emory UniversityMadhav V. Dhodapkar, Emory UniversityMehul S. Suthar, Emory UniversityJonathon B. Cohen, Emory UniversityRafi Ahmed, Emory University
    Date:2022
    Publisher:American Society of Clinical Oncology
    Publication Version:Final Published Version

  • SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients

    SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
    Authors:Erin M. Scherer, Emory UniversityAhmed Babiker, Emory UniversityMax W. Adelman, Emory UniversityBrent Allman, Emory UniversityAutum Key, Emory UniversityJennifer M. Kleinhenz, Emory UniversityRose M. Langsjoen, Emory UniversityPhuong-Vi Nguyen, Emory UniversityIvy Onyechi, Emory Universityjacob D. Sherman, Emory UniversityTrevor W. Simon, Emory UniversityHannah Soloff, Emory UniversityJessica Tarabay, Emory UniversityJay Varkey, Emory UniversityAndrew S. Webster, Emory UniversityDaniela Weiskopf, La Jolla Institute for ImmunologyDaniel B. Weissman, Emory UniversityYongxian Xu, Emory UniversityJesse J. Waggoner, Emory UniversityKatia Koelle, Emory UniversityNadine Rouphael, Emory UniversityStephanie M. Pouch, Emory UniversityAnne Piantadosi, Emory University
    Date:2022
    Publisher:Massachusetts Medical Society
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial 4.0 International

  • Unrecognized introductions of SARS-CoV-2 into the US state of Georgia shaped the early epidemic

    Unrecognized introductions of SARS-CoV-2 into the US state of Georgia shaped the early epidemic
    Authors:Ahmed Babiker, Emory UniversityMichael A. Martin, Emory UniversityCharles Marvil, Emory UniversityStephanie Bellman, Emory UniversityRobert A. Petit III, Emory UniversityHeath L. Bradley, Emory UniversityVictoria D. Stittleburg, Emory UniversityJessica Ingersoll, Emory UniversityColleen S. Kraft, Emory UniversityYan Li, Centers for Disease Control and PreventionJing Zhang, Centers for Disease Control and PreventionClinton R. Paden, Centers for Disease Control and Prevention, AtlantaTimothy D. Read, Emory UniversityJesse J. Waggoner, Emory UniversityKatia Koelle, Emory UniversityAnne Piantadosi, Emory University
    Date:2022
    Publisher:Oxford University Press
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial 4.0 International

  • Recombinant SARS-CoV-2 genomes circulated at low levels over the first year of the pandemic

    Recombinant SARS-CoV-2 genomes circulated at low levels over the first year of the pandemic
    Authors:David VanInsberghe, Emory UniversityAndrew S. Neish, Emory UniversityAnice C. Lowen, Emory UniversityKatia Hoelle, Emory University
    Date:2021
    Publisher:Oxford University Press
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates

    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates
    Authors:Molly E. Gallagher, Emory UniversityAndrew J. Sieben, Emory UniversityKristin N. Nelson, Emory UniversityAlicia N.M. Kraay, Emory UniversityWalter A. Orenstein, Emory UniversityBen Lopman, Emory UniversityAndreas Handel, University of Georgia, AthensKatia Koelle, Emory University
    Date:2021
    Publisher:Springer Nature
    Publication Version:Author Accepted Manuscript (After Peer Review)

  • Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines

    Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines
    Authors:Stephen Pelly, Emory UniversityDennis Liotta, Emory University
    Date:2021
    Publisher:American Chemical Society
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Informatics and Computational Approaches for the Discovery and Optimization of Natural Product-Inspired Inhibitors of the SARS-CoV-2 2′-O-Methyltransferase

    Informatics and Computational Approaches for the Discovery and Optimization of Natural Product-Inspired Inhibitors of the SARS-CoV-2 2′-O-Methyltransferase
    Authors:George S. Hanna, Medical University of South CarolinaMenny M. Benjamin, Medical University of South CarolinaYeun-Mun Choo, University of MalayaRamyani De, Emory UniversityRaymond F. Schinazi, Emory UniversitySarah E. Nielson, Utah State UniversityJoan M. Hevel, Utah State UniversityMark T. Hamann, Medical University of South Carolina
    Date:2024
    Publisher:American Chemical Society and American Society of Pharmacognosy
    Publication Version:Final Published Version
    License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

  • Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries

    Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries
    Authors:Dario Akaberi, Uppsala UniversityMonireh Pourghasemi Lati, Uppsala UniversityJanina Krambrich, Uppsala UniversityJulia Berger, Uppsala UniversityGrace Neilsen, Emory UniversityEmilia Strandback, Karolinska InstitutetS. Pauliina Turunen, KTH Royal Institute of TechnologyJohna Wannberg, Uppsala UniversityHjalmar Gullberg, Stockholm UniversityMartin Moche, Karolinska InstitutetPraveen Kumar Chinthakindi, Uppsala UniversityTomas Nyman, Karolinska InstitutetStefan G. Sarafianos, Emory UniversityAnja Sandström, Uppsala UniversityJosef D. Järhult, Uppsala UniversityKristian Sandberg, Uppsala UniversityÅke Lundkvist, Uppsala UniversityOscar Verho, Uppsala UniversityJohan Lennerstrand, Uppsala University
    Date:2024
    Publisher:American Society for Microbiology
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International

  • First detection of Omicron variant BA.4.1 lineage in dogs, Chile

    First detection of Omicron variant BA.4.1 lineage in dogs, Chile
    Authors:B. Agüero, Universidad de ChileF. Berrios, Universidad de ChileC. Pardo-Roa, Pontificia Universidad Católica de ChileN. Ariyama, Universidad de ChileB. Bennett, Universidad de ChileR.A. Medina, Pontificia Universidad Católica de ChileV. Neira, Universidad de Chile
    Date:2024
    Publisher:Informa UK Limited, trading as Taylor & Francis Group
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International